OncoMatch/Clinical Trials/NCT05754749
Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
Is NCT05754749 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Iohexol 350 Mg/mL Injectable Solution for breast cancer.
Treatment: Iohexol 350 Mg/mL Injectable Solution — The purpose of this pilot study is to compare radiologist confidence level in evaluating patients with known breast lesions between contrast enhanced digital breast tomosynthesis (CE- DBT) and contrast enhanced dynamic magnetic resonance imaging (CE-MRI) acquired as a part of a standard clinical workup.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Demographics
Lab requirements
Kidney function
serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels within the last 30 days prior to the research scan unless anuric and on dialysis
Impaired kidney function (serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels within the last 30 days prior to the research scan) unless anuric and on dialysis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of North Carolina at Chapel Hill · Chapel Hill, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05754749 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages